Blood group A linked to a higher risk of primary biliary cholangitis
A major retrospective study shows that people with blood group A face a higher likelihood of autoimmune liver…
Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)
In recent weeks, Gilead Sciences announced Health Canada’s conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and…